Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HNO-2: Cetuximab vs 5-FU in Induction for HNSCC
NCT01884259Phase 2Completed
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- May 2013
- Primary completion
- Jan 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Started May 2013; status: completed.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01884259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01884259.